research La FDA aprueba Litfulo® (ritlecitinib) para el tratamiento de la alopecia areata grave en adolescentes y adultos
The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.
Search
for
Sort by
Research
750-780 / 1000+ results 
research SUSPECTED CUTANEOUS DRUG TOXICITY IN RHEUMATOID ARTHRITIS—AN EVALUATION
Most skin rashes in rheumatoid arthritis patients were not caused by their medication, and careful evaluation allowed most to keep taking their beneficial treatment.
research Baricitinib: From Rheumatoid Arthritis to COVID‐19
Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
research 294 Extensive alopecia areata is reversed by IL-12/23p40 cytokine antagonism
Blocking certain proteins can significantly regrow hair in severe alopecia areata.
research Cutaneous side effects caused by treatment for inflammatory bowel disease
Some treatments for inflammatory bowel disease can cause skin problems like rashes and melanoma.
research A Prospective, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of a Cream Containing Xyloglucan, Pea Protein, and Opuntia ficus-indica Extract Versus Calcipotriol/Betamethasone in Adult Patients with Mild-to-moderate Psoriasis.
The cream with xyloglucan, pea protein, and cactus extract works as well as the standard treatment for psoriasis and is well-tolerated.
research Alopecia Areata – Effects of Treatment with Upadacitinib – Two Case Reports
Upadacitinib can effectively regrow hair in alopecia areata patients without worsening sarcoidosis.
research 061 Selective inhibition of tyrosine kinase 2 prevents and restores interleukin-12-induced hair follicle immune privilege collapse: a novel approach to alopecia areata therapy?
Blocking IL-12 can help treat alopecia areata by preventing hair follicle immune issues.
research 448 Challenges of securing insurance approval for oral tofacitinib treatment of alopecia areata: A multi-institutional retrospective review
Getting insurance to cover the hair loss treatment tofacitinib is hard because it's not officially approved for that use.
research Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies
Modern skin cancer treatments can cause skin side effects and hair loss, affecting patients' quality of life.
research Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study
Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.
research 43647 Treatment of Refractory Folliculitis Decalvans with the Topical JAK Inhibitor Tofacitinib
Topical tofacitinib helped a man with severe scalp condition after other treatments failed.
research 1457 CellutomeTM epidermal harvesting system and in vivo reflectance confocal microscopy as a novel wound healing assessment protocol
The new protocol using Cellutome™ and RCM safely assesses wound healing in detail.
research Intralesional Injection of Triamcinolone Acetonide, Methotrexate and Vitamin D in Treatment of Alopecia Areata: A Narrative Review
Methotrexate and vitamin D3 are potentially more effective and safer than triamcinolone for treating localized alopecia areata.
research Pharmacotherapy of alopecia areata
JAK inhibitors and combination therapies show promise for treating severe alopecia areata.
research 688 Precise and efficient editing of the COL7A1 gene in RDEB derived iPSCs with CRISPR/Cas9 and prime editing
CRISPR/Cas9 and prime editing can potentially fix skin disorder genes safely and effectively.
research Alefacept for Alopecia Areata
Alefacept showed some effectiveness for alopecia areata but needs more research.
research Advances in Stem Cell Therapy: Specific Applications in the Treatment of Cutaneous Radiation Syndrome
Stem cell therapy improves healing and reduces pain in cutaneous radiation syndrome.
research Case report of novel combination of anthralin and calcipotriene leading to trichologic response in alopecia areata
A new mix of anthralin and calcipotriene might help treat severe hair loss.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research Controlled Delivery of T-box21 Small Interfering RNA Ameliorates Autoimmune Alopecia (Alopecia Areata) in a C3H/HeJ Mouse Model
Controlled delivery of specific RNA and IL-4 restored hair growth in mice with autoimmune alopecia.
research Challenges, Progress, and Prospects of Developing Therapies to Treat Autoimmune Diseases
More precise, personalized therapies are needed for autoimmune diseases.
research 269 Down-regulatory role of cholecystokinin on psoriatic epidermal inflammation
Cholecystokinin may help reduce skin inflammation in psoriasis.
research High‐dose pulsed corticosteroid therapy combined with methotrexate for severe alopecia areata of childhood
High-dose corticosteroids and methotrexate had a modest effect on severe childhood alopecia, but side effects and relapse were concerns.
research Diphencyprone in the treatment of Satoyoshi syndrome
Azathioprine treatment led to rapid hair regrowth in a woman with alopecia universalis.
research 331 An open label clinical trial of the JAK inhibitor tofacitinib for alopecia areata
Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
research Adverse Reactions to Biologic Medications Used in Allergy and Immunology Diseases
Biologic therapies can cause various adverse events, but allergy/immunology clinicians can manage them.
research Psoriasis Course in Patients with Alopecia Areata Undergoing Baricitinib Therapy
Baricitinib helps alopecia areata and may improve psoriasis, but its effect on psoriatic arthritis is unclear.
research Home‐based diphenylcyclopropenone immunotherapy for alopecia areata: A large retrospective study of 94 cases
research Provenge is Talk of GU Malignancies Congress
Provenge extends prostate cancer survival by about 4 months.